Navigation

Thrombocytopenic purpura - romiplostim

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura

Status: History
Expected date of issue: TBC
Process: STA
Topic area:
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Joao Vieira
Communications manager: Shalu Kanal
Project manager: Jeremy Powell
Assessment Group / Evidence Review Group: Aberdeen HTA Group
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 24 October 2008
1st appraisal committee meeting: 03 February 2009
2nd appraisal committee meeting 01 April 2009
3rd appraisal committee meeting: 04 November 2010
4th appraisal committee meeting: 03 February 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Amgen (romiplostim)

Patient/carer groups

  • ITP Support Association

Professional groups

  • British Society for Haematology
  • British Committee for Standards in Haematology
  • National Blood Service
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Eastern and Coastal Kent Teaching PCT
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • A H Pharmaceuticals (azathioprine) (CA&U not returned, not participating)
  • Actavis UK (azathioprine, dapsone)
  • Arrow Generics (azathioprine) (CA&U not returned, not participating)
  • Baxter BioScience (intravenous anti-D immunoglobulin)
  • Bio Products Laboratory (intravenous normal immunoglobulin)
  • CSL Behring (intravenous normal immunoglobulin)
  • Dowelhurst (azathioprine) (CA&U not returned, not participating)
  • Focus Pharmaceuticals (azathioprine)
  • Generics UK (azathioprine, danazol) (CA&U not returned, not participating)
  • Genus Pharmaceuticals (vinblastine) (declined to participate)
  • GlaxoSmithKline UK (azathioprine)
  • Grifols UK (intravenous normal immunoglobulin) (CA&U not returned, not participating)
  • Hospira UK (vinblastine sulphate, vincristine sulphate) (CA&U not returned, not participating)
  • Novartis (cyclosporin) (declined to participate)
  • Pharmacia (cyclophosphamide)
  • Roche Products (mycophenolate mofetil, rituximab) (declined to participate)
  • Sanofi-Aventis (danazol) (CA&U not returned, not participating)

Relevant research groups

  • None

Evidence review group

  • Aberdeen HTA Group
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update
03 February 2009 The Committee met to discuss this appraisal on 3 February. Due to the weather-related travel problems the Committee was not quorate and was therefore not able to take any decisions. The appraisal will be discussed at the Committee's meeting on 1 April.
30 April 2009 The manufacturer of the drug has informed us that the date on which this drug will be launched in the UK has not been finalised and that the final price of the drug has not been formally announced. We therefore cannot release the decision agreed by the Committee and the evidence documentation related to the appraisal at this time.
14 October 2009 The manufacturer has now formally announced the final price of the drug. The appraisal can recommence in line with the normal STA process.
04 January 2010 The manufacturer of romiplostim are submitting a Patient Access Scheme. This scheme will need to be formally considered by the Department of Health. The Evidence Review Group will then need to critique the manufacturer’s assessment of the scheme.
Top


 

Key documents

This page was last updated: 19 May 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.